Giuseppe Palmieri

List of Publications by Year
in descending order

162	15,856	87723 38	17546 121
papers	citations	h-index	g-index

175	175	175	21353
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.	13.7	9,374
2	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	1.8	563
3	BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. Journal of Clinical Oncology, 2012, 30, 2522-2529.	0.8	419
4	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology, 2014, 3, e28780.	2.1	318
5	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. , 2018, 6, 74.		292
6	Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells. Cancer Research, 2004, 64, 3037-3045.	0.4	233
7	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 675-683.	2.0	230
8	Main roads to melanoma. Journal of Translational Medicine, 2009, 7, 86.	1.8	157
9	Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. Cancer Cell, 2004, 5, 137-149.	7.7	132
10	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clinical Immunology, 2010, 134, 237-250.	1.4	131
11	X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3311-3314.	3.3	121
12	A functional mammalian target of rapamycin complex 1 signaling is indispensable for câ€Mycâ€driven hepatocarcinogenesis. Hepatology, 2017, 66, 167-181.	3.6	119
13	NF-Î°B as potential target in the treatment of melanoma. Journal of Translational Medicine, 2012, 10, 53.	1.8	118
14	Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. Journal of Clinical Oncology, 1999, 17, 304-304.	0.8	109
15	Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. Molecular Cancer, 2007, 6, 8.	7.9	106
16	MC1R variants increased the risk of sporadic cutaneous melanoma in darkerâ€pigmented <scp>C</scp>aucasians: A pooledâ€analysis from the Mâ€SKIP project. International Journal of Cancer, 2015, 136, 618-631.	2.3	92
17	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptaseâ€“Polymerase Chain Reaction. Journal of Clinical Oncology, 2003, 21, 767-773.	0.8	91
18	Identification of a novel candidate gene,CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer. Human Mutation, 2004, 23, 318-326.	1.1	86

#	Article	IF	Citations
19	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Journal of Translational Medicine, 2017, 15, 46.	1.8	85
20	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Frontiers in Oncology, 2015, 5, 183.	1.3	80
21	Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 612.	1.8	79
22	Distribution and significance of 14-3-3Ïƒ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. Journal of Pathology, 2004, 202, 274-285.	2.1	67
23	Antitumoral effect of vanadium compounds in malignant melanoma cell lines. Journal of Inorganic Biochemistry, 2017, 174, 14-24.	1.5	66
24	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. Journal of Clinical Oncology, 2001, 19, 1437-1443.	0.8	63
25	Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches. Current Oncology Reports, 2018, 20, 86.	1.8	61
26	BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study. Journal of Clinical Oncology, 2004, 22, 286-292.	0.8	55
27	Long non-coding RNA CASC2 in human cancer. Critical Reviews in Oncology/Hematology, 2017, 111, 31-38.	2.0	54
28	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
29	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Research, 2005, 15, 235-244.	0.6	50
30	Genetic alterations in main candidate genes during melanoma progression. Oncotarget, 2018, 9, 8531-8541.	0.8	50
31	YAC Contig Organization and CpG Island Analysis in Xq28. Genomics, 1994, 24, 149-158.	1.3	44
32	Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Molecular Cancer, 2010, 9, 137.	7.9	44
33	The iduronate sulfatase gene: Isolation of a 1.2-Mb YAC contig spanning the entire gene and identification of heterogeneous deletions in patients with Hunter syndrome. Genomics, 1992, 12, 52-57.	1.3	43
34	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Journal of Translational Medicine, 2014, 12, 216.	1.8	43
35	Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Journal of Translational Medicine, 2016, 14, 292.	1.8	43
36	Separation surgery for metastatic epidural spinal cord compression: A qualitative review. Journal of Bone Oncology, 2020, 25, 100320.	1.0	43

#	Article	IF	Citations
37	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer, 2009, 9, 352.	1.1	42
38	Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways. Metallomics, 2019, 11, 1687-1699.	1.0	41
39	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. Journal of Translational Medicine, 2017, 15, 17.	1.8	40
40	Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. Cancer, 2002, 94, 3157-3168.	2.0	39
41	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-Î± 2b treatment. Journal of Translational Medicine, 2010, 8, 76.	1.8	39
42	Human glucose-6-phosphate dehydrogenase gene carried on a yeast artificial chromosome encodes active enzyme in monkey cells. Genomics, 1990, 7, 531-534.	1.3	38
43	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. BMC Cancer, 2013, 13, 17.	1.1	38
44	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. Journal of Molecular Diagnostics, 2019, 21, 756-767.	1.2	37
45	Actin-Binding Protein (ABP-280) Filamin Gene (FLN) Maps Telomeric to the Color Vision Locus (R/GCP) and Centromeric to G6PD in Xq28. Genomics, 1993, 17, 496-498.	1.3	36
46	Unexpected Distribution of <i>cKIT</i> and <i>BRAF</i> Mutations among Southern Italian Patients with Sinonasal Melanoma. Dermatology, 2013, 226, 279-284.	0.9	36
47	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Research, 2003, 13, 167-170.	0.6	35
48	Antitumor Activity of BRAF Inhibitor and IFNÎ± Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute, 2016, 108, djv435.	3.0	35
49	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. OncoImmunology, 2017, 6, e1283462.	2.1	34
50	NF-Î²B is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. Journal of Translational Medicine, 2012, 10, 252.	1.8	32
51	Breast Nodular Fasciitis: A Comprehensive Review. Breast Care, 2016, 11, 270-274.	0.8	32
52	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. Journal of the American Academy of Dermatology, 2016, 74, 325-332.	0.6	32
53	High-resolution methylation analysis of thehMLH1 promoter in sporadic endometrial and colorectal carcinomas. Cancer, 2003, 98, 1540-1546.	2.0	31
54	Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. Journal of Translational Medicine, 2012, 10, 178.	1.8	31

#	Article	IF	Citations
55	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. Journal of Translational Medicine, 2013, 11, 202.	1.8	31
56	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. Cancer Treatment Reviews, 2018, 69, 21-28.	3.4	31
57	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Letters, 2009, 274, 331-336.	3.2	30
58	Vitamin D status and risk for malignant cutaneous melanoma: recent advances. European Journal of Cancer Prevention, 2017, 26, 532-541.	0.6	30
59	Lung cancer epidemiology in North Sardinia, Italy. Multidisciplinary Respiratory Medicine, 2013, 8, 45.	0.6	29
60	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC Pulmonary Medicine, 2019, 19, 209.	0.8	29
61	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. European Journal of Cancer, 2007, 43, 137-143.	1.3	28
62	The immuneâ€related role of BRAF in melanoma. Molecular Oncology, 2015, 9, 93-104.	2.1	28
63	Association of polo-like kinase with Î±-, Î²- and Î³-tubulins in a stable complex. Biochemical Journal, 1999, 339, 435.	1.7	27
64	New paradigm for stage III melanoma: from surgery to adjuvant treatment. Journal of Translational Medicine, 2019, 17, 266.	1.8	27
65	An archipelago of CpG islands in Xq28: identification and fine mapping of 20 new CpG islands of the human X chromosome. Human Molecular Genetics, 1992, 1, 275-280.	1.4	26
66	Do BRAF inhibitors select for populations with different disease progression kinetics?. Journal of Translational Medicine, 2013, 11, 61.	1.8	25
67	Spectrum and prevalence ofBRCA1 andBRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer, 2005, 104, 1172-1179.	2.0	24
68	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	24
69	Discrepant alterations in main candidate genes among multiple primary melanomas. Journal of Translational Medicine, 2014, 12, 117.	1.8	24
70	Epidemiology and genetic susceptibility of malignant melanoma in North Sardinia, Italy. European Journal of Cancer Prevention, 2017, 26, 263-267.	0.6	24
71	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. BMC Cancer, 2019, 19, 772.	1.1	24
72	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. Journal of Translational Medicine, 2019, 17, 289.	1.8	24

#	Article	IF	Citations
73	Proteomic Profiling of Human Melanoma Metastatic Cell Line Secretomes. Journal of Proteome Research, 2011, 10, 4703-4714.	1.8	23
74	Phenotype characterization of human melanoma cells resistant to dabrafenib. Oncology Reports, 2017, 38, 2741-2751.	1.2	22
75	Fluorescence-Guided Surgery for High-Grade Gliomas: State of the Art and New Perspectives. Technology in Cancer Research and Treatment, 2021, 20, 153303382110216.	0.8	22
76	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-Î± in advanced malignant melanoma. Journal of Translational Medicine, 2013, 11, 38.	1.8	21
77	Molecular changes induced by the curcumin analogue D6 in human melanoma cells. Molecular Cancer, 2013, 12, 37.	7.9	21
78	KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncology Letters, 2014, 8, 1422-1426.	0.8	21
79	Female Adnexal Tumors of Probable Wolffian Origin (FATWO): A Case Series With Next-Generation Sequencing Mutation Analysis. International Journal of Gynecological Pathology, 2017, 36, 575-581.	0.9	21
80	CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. Melanoma Research, 2009, 19, 142-145.	0.6	20
81	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer, 2006, 6, 266.	1.1	19
82	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncology Reports, 2011, 25, 1495-502.	1.2	19
83	Prognostic impact of regression in patients with primary cutaneous melanoma >1Âmm in thickness. Journal of the American Academy of Dermatology, 2019, 80, 99-105.e5.	0.6	19
84	A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population. BMC Cancer, 2009, 9, 245.	1.1	18
85	Reproductive aging-associated common genetic variants and the risk of breast cancer. Breast Cancer Research, 2012, 14, R54.	2.2	17
86	Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. Oncotarget, 2017, 8, 90638-90650.	0.8	17
87	Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. International Journal of Molecular Sciences, 2018, 19, 47.	1.8	17
88	Presence of Jaagsiekte sheep retrovirus in tissue sections from human bronchioloalveolar carcinoma depends on patients' geographical origin. Human Pathology, 2008, 39, 303-304.	1.1	16
89	Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer, 2009, 9, 62.	1.1	16
90	Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncology Letters, 2014, 7, 948-952.	0.8	16

#	Article	IF	Citations
91	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: AÂPooled Analysis from the M-Skip Project. Journal of Investigative Dermatology, 2016, 136, 1914-1917.	0.3	16
92	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16
93	The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. Oncotarget, 2017, 8, 80393-80404.	0.8	16
94	Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. BMC Cancer, 2007, 7, 132.	1.1	15
95	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. Journal of Translational Medicine, 2015, 13, 37.	1.8	15
96	1.5-Mb YAC Contig in Xq28 Formatted with Sequence-Tagged Sites and Including a Region Unstable in the Clones. Genomics, 1993, 16, 586-592.	1.3	14
97	Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Molecular Medicine Reports, 2015, 12, 187-191.	1.1	14
98	Parental Use and Educational Campaigns on Sunbed Use Among Teenagers and Adolescents. Medicine (United States), 2016, 95, e3034.	0.4	14
99	Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies. Journal of Clinical Oncology, 2007, 25, e20-e21.	0.8	13
100	The role of spectrophotometry in the diagnosis of melanoma. BMC Dermatology, 2010, 10, 5.	2.1	13
101	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. Journal of Investigative Dermatology, 2016, 136, 1917-1920.	0.3	13
102	Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective. Nutrition and Metabolism, 2019, 16, 33.	1.3	13
103	Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. BMC Medical Research Methodology, 2012, 12, 116.	1.4	12
104	Genome-wide association study of susceptibility loci for breast cancer in Sardinian population. BMC Cancer, 2015, 15, 383.	1.1	12
105	Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. International Journal of Oncology, 2018, 53, 1149-1159.	1.4	12
106	Primary Melanoma of the Lung: A Systematic Review. Medicina (Lithuania), 2020, 56, 576.	0.8	12
107	Mutation analysis of candidate genes in melanoma-prone families. Melanoma Research, 2003, 13, 571-579.	0.6	11
108	Classic follicular dendritic reticulum cell tumor of the lymph node developing in a patient with a previous inflammatory pseudotumorâ€“like proliferation. Human Pathology, 2005, 36, 207-211.	1.1	11

#	Article	IF	Citations
109	A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. Cell Cycle, 2009, 8, 1228-1237.	1.3	11
110	Monitoring liver alterations during hepatic tumorigenesis by NMR profiling and pattern recognition. Metabolomics, 2010, 6, 405-416.	1.4	11
111	Molecular alterations in key-regulator genes among patients with T4 breast carcinoma. BMC Cancer, 2010, 10, 458.	1.1	11
112	Epidemiology of Thyroid Cancer in an Area of Epidemic Thyroid Goiter. Journal of Cancer Epidemiology, 2013, 2013, 1-4.	0.5	11
113	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiReÂ® Panel. Frontiers in Oncology, 2020, 10, 236.	1.3	11
114	Adjuvant treatment of malignant melanoma: Where are we?. Critical Reviews in Oncology/Hematology, 2006, 57, 45-52.	2.0	10
115	Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. Journal of Translational Medicine, 2017, 15, 227.	1.8	10
116	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. Journal of Clinical Medicine, 2020, 9, 2430.	1.0	10
117	NGS-Based Analysis of Atypical Deep Penetrating Nevi. Cancers, 2021, 13, 3066.	1.7	10
118	A Study of Inflammatory/Necrosis Biomarkers in the Fracture of the Femur Treated with Proximal Femoral Nail Antirotation. Mediators of Inflammation, 2015, 2015, 1-5.	1.4	9
119	Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. Retrovirology, 2017, 14, 3.	0.9	9
120	BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. Journal of Clinical Medicine, 2019, 8, 1577.	1.0	9
121	Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. BMC Dermatology, 2009, 9, 7.	2.1	8
122	Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis. Journal of Investigative Dermatology, 2013, 133, 1685-1687.	0.3	8
123	ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. Journal of Translational Medicine, 2014, 12, 272.	1.8	8
124	Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6. BMC Cancer, 2016, 16, 317.	1.1	8
125	Primary Dermal Melanoma in a Patient with a History of Multiple Malignancies: A Case Report with Molecular Characterization. Case Reports in Dermatology, 2013, 5, 192-197.	0.3	7
126	Estimates of cancer burden in Sardinia. Tumori, 2013, 99, 408-415.	0.6	7

#	Article	IF	Citations
127	Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases. Metabolomics, 2014, 10, 1026-1035.	1.4	7
128	Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art. Current Medicinal Chemistry, 2021, 28, 2234-2247.	1.2	7
129	Estimates of cancer burden in Sardinia. Tumori, 2013, 99, 408-15.	0.6	7
130	Construction of a pilot human YAC library in a recombination-defective yeast strain. Gene, 1997, 188, 169-174.	1.0	6
131	Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature. Clinical Respiratory Journal, 2018, 12, 848-856.	0.6	6
132	Significance of Methotrexate Serum Level Achieved in Patients with Gastrointestinal Malignancies Treated with Sequential Methotrexate, <i>L</i>-Folinic Acid and 5-Fluorouracil. Oncology, 1996, 53, 198-203.	0.9	5
133	Molecular analysis of appendiceal mucinous cystadenoma and rectal adenocarcinoma in a patient with urothelial carcinoma: a case report. Journal of Medical Case Reports, 2013, 7, 170.	0.4	5
134	Management of Small and Intermediate Congenital Nevi: A Nationwide Survey in Italy. Dermatology, 2013, 226, 7-12.	0.9	5
135	Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations. European Journal of Dermatology, 2018, 28, 149-156.	0.3	5
136	Perivascular Epithelioid Cell Tumors (PEComas) of the Orbit. Journal of Pathology and Translational Medicine, 2017, 51, 7-8.	0.4	5
137	Identification of predictive factors for the occurrence of predisposing MLH1 and MSH2 germline mutations among Sardinian patients with colorectal carcinoma. European Journal of Cancer, 2005, 41, 1058-1064.	1.3	4
138	2,2â€²-Dihydroxy-3,3â€²-dimethoxy-5,5â€²-dimethyl-6,6â€²-dibromo-1,1â€²-biphenyl: preparation, resolution, structure and biological activity. Tetrahedron: Asymmetry, 2007, 18, 414-423.	1.8	4
139	Second primary melanoma on a patient undergoing vemurafenib therapy. A case report. International Journal of Dermatology, 2017, 56, 792-794.	0.5	4
140	The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?. International Journal of Molecular Sciences, 2021, 22, 7160.	1.8	4
141	The Relevant Role of Navigated Tractography in Speech Eloquent Area Glioma Surgery: Single Center Experience. Brain Sciences, 2021, 11, 1436.	1.1	4
142	Human dbl proto-oncogene in 85 kb of Xq26, and determination of the transcription initiation site. Gene, 2000, 253, 107-115.	1.0	3
143	Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. Oncology Letters, 2016, 12, 1415-1421.	0.8	3
144	Impact of Mole Mapping in the Italian Health System. Dermatology, 2013, 226, 13-17.	0.9	2

#	Article	IF	Citations
145	Diagnostic Services for Melanoma in Italy. Dermatology, 2013, 226, 3-6.	0.9	2
146	Epidemiological features and prognostic parameters of multiple primary melanomas inCDKN2A-mutations patients. Pigment Cell and Melanoma Research, 2015, 28, 747-751.	1.5	2
147	Sunburn-related variables, secular trends of improved sun protection and short-term impact on sun attitude behavior in Italian primary schoolchildren. Medicine (United States), 2020, 99, e18078.	0.4	2
148	Genetic Instability Markers in Cancer. Methods in Molecular Biology, 2020, 2055, 133-154.	0.4	2
149	What is changing in the adjuvant treatment of melanoma?. Oncotarget, 2017, 8, 110735-110736.	0.8	2
150	Doseâ€“Finding Study of 5’-Deoxy-5-Fluorouridine in Combination with Fixed Doses of Cisplatin and <i>L</i>-Folinic Acid for the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck. Oncology, 1995, 52, 326-330.	0.9	1
151	Melanoma: From Research to Treatment. Journal of Skin Cancer, 2011, 2011, 1-2.	0.5	1
152	Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. Oncology Reports, 2011, 25, 899-904.	1.2	1
153	Surgical Management of Suspicious Melanocytic Lesions in Italy. Dermatology, 2013, 226, 18-21.	0.9	1
154	The panitumumab with FOLFOX4 in metastatic gastric or gastroesophageal junction adenocarcinoma (mGA) - VEGA trial. Efficacy and safety outcomes of a phase II S.I.C.O.G. study. Annals of Oncology, 2017, 28, iii40.	0.6	1
155	Mobile hospital rooms to fight melanoma. Melanoma Research, 2001, 11, 83-84.	0.6	1
156	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0
157	The immune-related role of BRAF in melanoma. Journal of Translational Medicine, 2015, 13, K19.	1.8	0
158	Pathology and Genetics of Melanoma. , 2018, , .		0
159	Developmental Gene Markers in Tumor Pathogenesis and Progression. Disease Markers, 2019, 2019, 1-2.	0.6	0
160	Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases. Diagnostics, 2019, 9, 42.	1.3	0
161	Posterior arch reconstruction in cervical surgery to restore the global biomechanics of the Atlas: a technical note. British Journal of Neurosurgery, 2021, , 1-4.	0.4	0
162	Molecular Pathology of Melanocytic Skin Cancer. , 2014, , 59-74.		0